- Home
- REX vs NUVB Comparison
REX vs NUVB Comparison
Compare REX & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REX
- NUVB
- Stock Information
- Founded
- REX 1980
- NUVB 2018
- Country
- REX United States
- NUVB United States
- Employees
- REX N/A
- NUVB N/A
- Industry
- REX Major Chemicals
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- REX Industrials
- NUVB Health Care
- Exchange
- REX Nasdaq
- NUVB Nasdaq
- Market Cap
- REX 1.1B
- NUVB 1.1B
- IPO Year
- REX N/A
- NUVB N/A
- Fundamental
- Price
- REX $31.99
- NUVB $5.15
- Analyst Decision
- REX Strong Buy
- NUVB Strong Buy
- Analyst Count
- REX 1
- NUVB 7
- Target Price
- REX $25.00
- NUVB $8.43
- AVG Volume (30 Days)
- REX 174.7K
- NUVB 8.5M
- Earning Date
- REX 12-02-2025
- NUVB 11-03-2025
- Dividend Yield
- REX N/A
- NUVB N/A
- EPS Growth
- REX N/A
- NUVB N/A
- EPS
- REX 1.49
- NUVB N/A
- Revenue
- REX $650,008,000.00
- NUVB $14,355,000.00
- Revenue This Year
- REX $3.27
- NUVB $283.91
- Revenue Next Year
- REX $17.11
- NUVB $340.13
- P/E Ratio
- REX $21.44
- NUVB N/A
- Revenue Growth
- REX N/A
- NUVB 900.35
- 52 Week Low
- REX $16.73
- NUVB $1.54
- 52 Week High
- REX $33.77
- NUVB $5.55
- Technical
- Relative Strength Index (RSI)
- REX 39.59
- NUVB 73.02
- Support Level
- REX $31.48
- NUVB $3.36
- Resistance Level
- REX $32.60
- NUVB $5.55
- Average True Range (ATR)
- REX 1.03
- NUVB 0.33
- MACD
- REX 0.68
- NUVB 0.14
- Stochastic Oscillator
- REX 46.22
- NUVB 81.74
About REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.